Mechanism of clobazam-induced thyroidal oncogenesis in male rats.
In order to elucidate the mechanisms by which long-term treatment with clobazam (CLB), 1,5-benzodiazepine, induces thyroid follicular cell tumors in male rats, male Sprague-Dawley (SD) rats were treated orally with 400 mg/kg of CLB for up to 4 weeks, and the contribution of feedback through elevated thyroid stimulating hormone (TSH) was investigated. Measurements taken after 1, 2, and 4 weeks of treatment revealed that thyroxine (T4)-UDP-glucuronosyltransferase (T4-UDPGT) activity was higher than that of untreated animals. This change was accompanied by increase in liver weights and centrilobular hepatocyte hypertrophy. In addition, plasma total triiodothyronine (T3) and T4 levels were lower than in the untreated rats when measured after 1 week of treatment. However, a high plasma TSH level was sustained throughout the 4-week treatment. Thyroid follicular cell hypertrophy began after 1 week of treatment, followed by increased thyroid weight after 2 weeks. Clearance of exogenous [125I] T4 from the blood of treated rats, determined after 4 weeks of treatment, was significantly faster than that in untreated rats, whereas iodine uptake and organification in the thyroid glands were not affected. These results suggest that CLB increases hepatic T4-UDPGT activity leading to acceleration of T4-clearance, which results in decreased plasma thyroidal hormones followed by compensatory increase of TSH biosynthesis and secretion. Chronic high levels of TSH would exert a continuous growth pressure on the thyroid, under which hypertrophic follicular cells can ultimately progress to frank neoplasms.
Safety Research Laboratories, Dainippon Pharmaceutical Co Ltd, 33-94, Enoki-cho, Suita, Osaka 564-0053, Japan. iduru-miyawaki@dainippon-pharm.co.jp
Izuru
I
Miyawaki
Matsuko
M
Moriyasu
Hitoshi
H
Funabashi
Masashi
M
Yasuba
Nobuo
N
Matsuoka
D000284:Administration, Oral; D000818:Animals; D000927:Anticonvulsants / Q000633:toxicity*; D001569:Benzodiazepines / Q000633:toxicity*; D000078306:Clobazam; D014453:Glucuronosyltransferase / Q000378:metabolism; D006984:Hypertrophy; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D008297:Male; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013961:Thyroid Gland / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D013964:Thyroid Neoplasms / Q000139:chemically induced; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D000927:Anticonvulsants; D014284:Triiodothyronine; D001569:Benzodiazepines; D000078306:Clobazam; D013972:Thyrotropin; C117189:thyroxine-UDP-glucuronosyltransferase; D014453:Glucuronosyltransferase; D013974:Thyroxine